{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T19:47:23Z","timestamp":1762285643369,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302974"],"award-info":[{"award-number":["82302974"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007289","name":"Nanjing Medical University","doi-asserted-by":"publisher","award":["ZJ202213","789ZYRC202080122","RCQY202402"],"award-info":[{"award-number":["ZJ202213","789ZYRC202080122","RCQY202402"]}],"id":[{"id":"10.13039\/501100007289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejogrb.2025.114707","type":"journal-article","created":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T22:29:25Z","timestamp":1757284165000},"page":"114707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Niraparib combined with anlotinib after PARPi resistance in ovarian cancer: A single-center retrospective study from China"],"prefix":"10.1016","volume":"314","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3513-4626","authenticated-orcid":false,"given":"Xianzhong","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luxin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuening","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yourong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejogrb.2025.114707_b0005","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10585-021-10136-5","article-title":"Molecular and cellular mechanisms controlling integrin-mediated cell adhesion and tumor progression in ovarian cancer metastasis: a review","volume":"39","author":"Dhaliwal","year":"2022","journal-title":"Clin Exp Metastasis"},{"issue":"9","key":"10.1016\/j.ejogrb.2025.114707_b0010","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/ijc.34165","article-title":"The prevalence of mismatch repair deficiency in ovarian cancer: a systematic review and meta-analysis","volume":"151","author":"Atwal","year":"2022","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.ejogrb.2025.114707_b0015","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial","volume":"157","author":"Lim","year":"2022","journal-title":"JAMA Surg"},{"issue":"1","key":"10.1016\/j.ejogrb.2025.114707_b0020","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1002\/onco.13551","article-title":"FDA approval summary: olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer","volume":"26","author":"Arora","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ejogrb.2025.114707_b0025","doi-asserted-by":"crossref","unstructured":"Santangelo G, Caruso G, Palaia I, Tomao F, Perniola G, Di Donato V, Fischetti M, Muzii L, Benedetti Panici PJERoPM, Development D: The emerging role of precision medicine in the treatment of ovarian cancer. 2020, 5(4):283-297.","DOI":"10.1080\/23808993.2020.1777854"},{"issue":"6","key":"10.1016\/j.ejogrb.2025.114707_b0030","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/13543784.2022.2067527","article-title":"PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers","volume":"31","author":"Luo","year":"2022","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.ejogrb.2025.114707_b0035","article-title":"Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status","volume":"16(1):6","author":"Wu","year":"2023","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.ejogrb.2025.114707_b0040","article-title":"Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China","volume":"12(1):117","author":"Ni","year":"2019","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.ejogrb.2025.114707_b0045","article-title":"The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China","volume":"14(1):68","author":"Ni","year":"2021","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.ejogrb.2025.114707_b0050","unstructured":"GSK provides an update on Zejula (niraparib) US prescribing information [https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-provides-an-update-on-zejula-niraparib-us-prescribing-information\/]."},{"key":"10.1016\/j.ejogrb.2025.114707_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101767","article-title":"A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study","volume":"54","author":"Liu","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ejogrb.2025.114707_b0060","doi-asserted-by":"crossref","unstructured":"Ji Y, Li X, Qi Y, Zhao J, Zhang W, Qu P: Anlotinib exerts inhibitory effects against cisplatin-resistant ovarian cancer in vitro and in vivo. Molecules 2022, 27(24).","DOI":"10.3390\/molecules27248873"},{"issue":"2","key":"10.1016\/j.ejogrb.2025.114707_b0065","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s10637-021-01179-2","article-title":"A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum\/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer","volume":"40","author":"Huang","year":"2022","journal-title":"Invest New Drugs"},{"issue":"4","key":"10.1016\/j.ejogrb.2025.114707_b0070","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/cam4.4507","article-title":"Anlotinib for patients with small cell lung cancer and baseline liver metastases: a post hoc analysis of the ALTER 1202 trial","volume":"11","author":"Cheng","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejogrb.2025.114707_b0075","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2147\/DDDT.S286529","article-title":"A retrospective observational study of anlotinib in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer","volume":"15","author":"Cui","year":"2021","journal-title":"Drug Des Devel Ther"},{"issue":"9","key":"10.1016\/j.ejogrb.2025.114707_b0080","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"6330","key":"10.1016\/j.ejogrb.2025.114707_b0085","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ejogrb.2025.114707_b0090","article-title":"HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer","volume":"13(3):263","author":"Ma","year":"2022","journal-title":"Cell Death Dis"},{"issue":"492","key":"10.1016\/j.ejogrb.2025.114707_b0095","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav4508","article-title":"Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1\/2 and RAD51","volume":"11","author":"Kaplan","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejogrb.2025.114707_b0100","doi-asserted-by":"crossref","unstructured":"Jin C, Yuan M, Bu H, Jin C: Antiangiogenic strategies in epithelial ovarian cancer: mechanism, resistance, and combination therapy. J Oncol 2022, 2022:4880355.","DOI":"10.1155\/2022\/4880355"},{"issue":"25","key":"10.1016\/j.ejogrb.2025.114707_b0105","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejogrb.2025.114707_b0110","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(19)30515-7","article-title":"Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2\/ENGOT-ov24): a randomised, phase 2, superiority trial","volume":"20","author":"Mirza","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejogrb.2025.114707_b0115","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejogrb.2025.114707_b0120","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney MJEjoc: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). 2009, 45(2):228-247.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"10.1016\/j.ejogrb.2025.114707_b0125","doi-asserted-by":"crossref","unstructured":"Lheureux S, Oaknin A, Garg S, Bruce JP, Madariaga A, Dhani NC, Bowering V, White J, Accardi S, Tan QJCCR: EVOLVE: a multicenter open-label single-arm clinical and translational phase II trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression. 2020, 26(16):4206-4215.","DOI":"10.1158\/1078-0432.CCR-19-4121"},{"key":"10.1016\/j.ejogrb.2025.114707_b0130","doi-asserted-by":"crossref","unstructured":"Lee J-M, Moore RG, Ghamande S, Park MS, Diaz JP, Chapman J, Kendrick J, Slomovitz BM, Tewari KS, Lowe ESJCCR: Cediranib in combination with olaparib in patients without a germline BRCA1\/2 mutation and with recurrent platinum-resistant ovarian cancer: phase IIb CONCERTO trial. 2022, 28(19):4186-4193.","DOI":"10.1158\/1078-0432.CCR-21-1733"},{"key":"10.1016\/j.ejogrb.2025.114707_b0135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejogrb.2025.01.038","article-title":"Safety of niraparib-based regimens in patients with ovarian cancer: a systematic review and meta-analysis","volume":"307","author":"Tayyab","year":"2025","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ejogrb.2025.114707_b0140","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejogrb.2024.12.021","article-title":"Haematological toxicity of PARP inhibitors in advanced ovarian cancer: a systematic review and meta-analysis","volume":"305","author":"Pio Maiorano","year":"2025","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"4","key":"10.1016\/j.ejogrb.2025.114707_b0145","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","article-title":"Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial\u2606","volume":"32","author":"Wu","year":"2021","journal-title":"Ann Oncol"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211525009832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211525009832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T19:43:24Z","timestamp":1762285404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211525009832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":29,"alternative-id":["S0301211525009832"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2025.114707","relation":{},"ISSN":["0301-2115"],"issn-type":[{"type":"print","value":"0301-2115"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Niraparib combined with anlotinib after PARPi resistance in ovarian cancer: A single-center retrospective study from China","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2025.114707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114707"}}